Respiri's Partnership with Ceras for Covenant Health Inc Contract

Respiri Limited (ASX:RSH; OTCQB: RSHUF) has announced a partnership with Ceras, a healthcare technology and AI organization, to provide remote patient services for Covenant Health Inc. The initial contract is valued at over A$1.1M and covers 750+ patients, with revenues contributing to the company's monthly profitability target by the end of 2024.

Executive Commentary on Partnership and Contract Details

Respiri CEO, Marjan Mikel, expressed excitement about the partnership with Covenant Health Inc, highlighting the alignment of visions in extending care beyond the hospital. The collaboration with Ceras also presents an opportunity to explore and develop AI and platform capabilities in healthcare delivery. The company is confident about securing more contracts from this collaboration in the near future and is in advanced discussions with other potential clients.

Summary of Respiri's Partnership and Future Outlook

Respiri's partnership with Ceras to deliver remote patient services for Covenant Health Inc marks a significant step towards achieving monthly profitability by the end of 2024. The initial contract, valued at over A$1.1M, demonstrates the company's capacity to scale its proven model and generate immediate revenue contributions. The integration with Covenant's EPIC EMR system and the focus on identifying high-risk patients reflect the company's commitment to improving patient care delivery and overall well-being. With ongoing discussions with potential clients and the expectation of more contracted business, Respiri looks forward to driving significant improvements in patient access and management, positioning itself at the forefront of chronic disease management in the US healthcare industry.